In the same context, MPOE-treated group 3 showed marked reductions in TGF-β1 and SMAD3 proteins expression (Figures 6(c) and 7(c)) compared to the CCl4 fibrosis group (Figures 6(b) and 7(b)). The gene discussed is SMAD3; the disease is fibrosis.